Advertisement
Organisation › Details
Pfizer (Group)
At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. *
Industry | pharmaceutical | |
Street | 235 East 42nd Street | |
City | 10017 New York, NY | |
Tel | +1-212-733-2323 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 48,613,000,000 (revenue, consolidated (2007) 2007-12-31) | |
Profit | 8,298,000,000 (2007-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Pfizer (Group)
- [1] AstraZeneca plc. (9/20/23). "Press Release: Alexion Completes Purchase and Licence Agreement for Early-stage Rare Disease Gene Therapy Portfolio from Pfizer"....
- [2] Flagship Pioneering. (7/18/23). "Press Release: Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs". Cambridge, MA & New York, NY....
- [3] Touchlight Genetics Ltd.. (7/6/22). "Press Release: Touchlight Signs Patent License Agreement with Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies". Hampton....
- [4] HBM Healthcare Investments Ltd.. (5/10/22). "Press Release: Pfizer to Acquire HBM Portfolio Company Biohaven Pharmaceuticals in USD 11.6 Billion Deal". Zug....
- [5] ReViral Ltd.. (4/7/22). "Press Release: Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates". New York, NY, London & Research Triangle Park, NC....
- [6] Mission Therapeutics Ltd.. (7/6/20). "Press Release: Mission Raises $15m and Expands its Relationship with Pfizer". Cambridge....
- [7] Artios Pharma Ltd.. (9/24/19). "Press Release: Artios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States". Cambridge & New York, NY....
- [8] Circassia Pharmaceuticals plc. (8/12/19). "Press Release: Circassia Appoints Industry Veteran Jonathan Emms as Chief Operating Officer". Oxford....
- [9] Sygnature Discovery Ltd.. (6/1/18). "Press Release: Sygnature Discovery Focuses on US Expansion with the Appointment of Dr Bill Marathias". Nottingham....
- [10] Basilea Pharmaceutica Ltd.. (1/10/18). "Press Release: Basilea Announces Completion of the License Agreement Extension with Pfizer for Antifungal Cresemba for China and Asia Pacific". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top